Yi-Hsiang Liu
Memorial Hospital of South Bend
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yi-Hsiang Liu.
Cancer Cell International | 2015
Chiung-Chi Cheng; Yen-Chang Clark Lai; Yih-Shyong Lai; Yung-Hsiang Hsu; Wei-Ting Chao; Kee-Chin Sia; Yu-Hui Tseng; Yi-Hsiang Liu
BackgroundPlectin is one of the cytolinker proteins that play a crucial role in maintaining the integrity of cellular architecture. It is a component of desmosome complexes connecting cytoskeletal proteins and trans-membrane molecules. In epithelial cells, plectin connects cytokeratins and integrin α6β4 in hemidesmosomes anchoring to the extracellular matrix. In addition to the function of molecular adherent, plectin has been reported to exhibit functions affecting cellular signals and responsive activities mediated by stress, cellular migration, polarization as well as the dynamic movement of actin filaments. Plectin deficiency in hepatocellular carcinoma results in abnormal expression of cytokeratin 18 and disassembled hemidesmosome. Therefore, it is hypothesized that the plectin deficiency-mediated collapse of cytoskeleton may modulate cellular motility that is associated with consequent metastatic behaviors of cancer cells.Methods and resultsThe cellular motility of plectin-deficient Chang liver cells generated by transient knockdown were analyzed by trans-well migration assay and the results revealed a higher migration rate. The confocal microscopy also demonstrated less organized and more polarized morphology as well as more focal adhesion kinase activity in comparison with that of the mock Chang liver cells. Furthermore, plectin-knockdown in Chang liver cells was associated with a higher activity of Rac1-GTPase in accordance with the results of the Rac1 pull-down assay. The immunohistochemical assay on human hepatocellular carcinoma showed that the expression of focal adhesion kinase was increased in the invasive front of tumor.ConclusionPlectin-deficient human hepatic cells exhibit higher cell motility associated with increase in focal adhesion kinase activity that are comparable to the properties of invasive hepatocellular carcinoma.
Biochemical and Biophysical Research Communications | 2011
Yi-Hsiang Liu; Chin-Chin Ho; Chiung-Chi Cheng; Wei-Ting Chao; Ren-Jeng Pei; Yung-Hsiang Hsu; Yih-Shyong Lai
Plectin is a cross-linking protein that organizes the cytoskeleton into a stable meshwork that helps maintain the uniform size and shape of cells. As cells of hepatocellular carcinoma are morphologically different from healthy human hepatocytes, we hypothesized that plectin deficiency and cytoskeletal disorganization underlies this pleomorphic transformation. To test this hypothesis we induced apoptosis as the most accessible pathway for creating plectin deficiency status in vivo. We analyzed expression levels and organization of plectin and other cytoskeletal elements, including intermediate filaments, microfilaments, and microtubules, after staurosporine-induced apoptosis in human Chang liver cells. The results revealed the expression of plectin and cytokeratin 18 were downregulated in hepatocellular carcinoma tissues in vivo. The expression of actin and tubulin, however, were not altered. In vitro analysis indicated that plectin and cytokeratin 18 were cleaved following staurosporine-treatment of human Chang liver cells. Time course experiments revealed that plectin was cleaved 2h earlier than cytokeratin 18. The organization of plectin and cytokeratin 18 networks collapsed after staurosporine-treatment. Conclusively, degradation of plectin induced by staurosporine-treatment in liver cells resulted in cytoskeleton disruption and induced morphological changes in these cells by affecting the expression and organization of cytokeratin 18.
Biochemical and Biophysical Research Communications | 2011
Yi-Hsiang Liu; Chiung-Chi Cheng; Yih-Shyong Lai; Wei-Ting Chao; Ren-Jeng Pei; Yung-Hsiang Hsu; Chin-Chin Ho
Synemin is a large intermediate filament protein that has been identified in all types of muscle cells. It plays a role in human muscle diseases; however, the role of synemin in tumor cell transformation has rarely been investigated. Because hepatocellular carcinoma cells are morphologically different from normal human hepatocytes, we hypothesized that altered synemin expression and cytoskeletal disorganization might underlie this pleomorphic transformation. To test this hypothesis, we studied synemin expression in hepatocellular carcinoma and liver tissues by immunohistochemistry and immunoblotting. In addition, we analyzed the expression level and organization of all cytoskeletal elements after synemin knock-down in human Chang liver cells. Previously we found that plectin knock-down in human Chang liver cells causes a reduction in cytokeratin 18 expression with effects on intermediate filament disorganization and altered cellular morphology. In this study we also compared the effects of synemin knock-down and plectin knock-down on the cytoskeleton expression and organization. The results revealed that synemin expression was down-regulated in human hepatocellular carcinoma compared with normal liver, which is similar to the plectin expression. Surprisingly, the expression of cytoskeletal elements (cytokeratin 18, actin and tubulin) was not influenced by synemin knock-down in human Chang liver cells. The organization of cytoskeletal networks was also unaltered after synemin knock-down. In conclusion, both plectin and synemin are down-regulated in human hepatocellular carcinoma in vivo and transformed human liver cell in vitro. However, the mechanism of cell transformation caused by synemin knock-down is different from that of plectin knock-down. Plectin, but not synemin, knock-down provoked liver cell transformation via suppressing cytokeratin 18 expression and disrupting intermediate filament networks. Synemin knock-down did not influence the cytoskeleton expression and organization of human Chang liver cells.
in Vivo | 2008
Chin-Chin Ho; Chiung-Chi Cheng; Yi-Hsiang Liu; Ren-Jeng Pei; Yung-Hsiang Hsu; Kun-Tu Yeh; Lu-Chang Ho; Ming-Chuang Tsai; Yih-Shyong Lai
in Vivo | 2008
Yi-Hsiang Liu; Chiung-Chi Cheng; Chin-Chin Ho; Wei-Ting Chao; Ren-Jeng Pei; Yung-Hsiang Hsu; Kun-Tu Yeh; Lu-Chang Ho; Ming-Chuang Tsai; Yih-Shyong Lai
Cancer Genomics & Proteomics | 2017
Yen-Chang Clark Lai; Chiung-Chi Cheng; Yih-Shyong Lai; Yi-Hsiang Liu
in Vivo | 2016
Chiung-Chi Cheng; Yen-Chang Clark Lai; Yih-Shyong Lai; Wei-Ting Chao; Yu-Hui Tseng; Yung-Hsiang Hsu; You-Yin Chen; Yi-Hsiang Liu
in Vivo | 2015
Chiung-Chi Cheng; Yi-Hsiang Liu; Yen-Chang Clark Lai; Yung-Hsiang Hsu; Wei-Ting Chao; Yih-Shyong Lai
Annals of Oncology | 2016
Yi-Hsiang Liu; Yen-Chang Clark Lai; Chiung-Chi Cheng; Yih-Shyong Lai
Annals of Oncology | 2016
Yih-Shyong Lai; Yen-Chang Clark Lai; Yi-Hsiang Liu; Chiung-Chi Cheng